$PMI

Picard Medical, Inc. (PMI) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On September 30, 2026 (the “Issuance Date”), Picard Medical, Inc. (the “Company”) issued three separate unsecured convertible notes (collectively, the “Not

Picard Medical's stock fell 14.5% in morning trading, reversing recent gains. The company has relied on equity issuances for funding, has a thin cash position, and lacks near-term catalysts. Broader market declines also contributed to the drop. The company is working to meet NYSE listing standards.

Picard Medical Inc. (PMI) shares rose 27% after Q2 2026 revenue of $2.954M beat estimates by 90.58%, up 38.62% YoY. Despite a loss of $(3.05) per share, investors focused on top-line growth and improved gross margins. The company is investing in R&D for its next-gen Emperor Total Artificial Heart, presenting new data at conferences. PMI completed a 1-for-50 reverse stock split in July 2026 to regain NYSE compliance.

Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

Picard Medical, Inc. (PMI) shares rose 40% after reporting Q2 2026 revenue growth of 39% to $3.0M, driven by U.S. sales of SynCardia products. Gross profit improved to $0.6M, and net loss narrowed by 16%. The company also advanced its Emperor Total Artificial Heart platform and completed a reverse stock split to comply with NYSE listing requirements.

Picard Medical Inc. stock surged 43.9% in pre-market trading after reporting Q2 2026 revenue of $2.95M, exceeding expectations of $1.55M. The company also issued an investor presentation. The S&P 500, Nasdaq, and Dow were down slightly, indicating the rally was company-specific.

Picard Medical reported Q2 2026 revenue growth of 39% to $3.0M, with a 16% reduction in net loss to $5.7M. Year-to-date revenue rose 50% to $4.1M, with $0.9M in gross profit. The company is advancing its Emperor Total Artificial Heart platform and focusing on operational improvements. PMI completed a 1-for-50 reverse stock split to comply with NYSE American listing standards.

Picard Medical reported a 50% revenue increase to $4.1M, driven by U.S. sales, but a wider net loss of $13.3M due to R&D and SG&A expenses. The company faces going concern risks, customer concentration, and litigation, while investing in next-gen heart tech.

Nicotine pouches are gaining investor attention as cigarette sales decline, with brands like PMI's Zyn and BAT's Velo showing rapid growth and strong margins. BAT expects the global pouch market to grow from £4B in 2025 to £11B by 2030, with pouch volumes in Asia, Middle East, and Africa up 27.5% in H1 2026. PMI reported higher profitability for pouches compared to cigarettes and heated tobacco. Analysts note that pouch performance influences tobacco-company valuations, but wider adoption faces